Global /Japan /Healthcare /Drug Manufacturers - Specialty & Generic /7776

CellSeed Inc.

7776

• TSE: 7776 • Delayed

269JPY -3.9%

1.68 USD

As of 13 June 2026, CellSeed Inc. has a market cap of $67.3M USD, ranking #28372 globally and #2569 in Japan. It ranks #2570 in the Healthcare sector, and #141 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

28372

Country Rank

2569

Sector Rank

2570

Industry Rank

141

Key Stats

Market Cap

$67.3MUSD

10.77B JPY

Revenue (TTM)

$1.01MUSD

161.0M JPY

EBITDA (TTM)

-$5.38MUSD

-863.0M JPY

Net Income (TTM)

-$5.71MUSD

-914.0M JPY

PS Ratio

66.9

PB Ratio

10.5

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Setsuko Hashimoto open_in_new

Employees

Founded

2001

Website

cellseed.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.9%	-7.6%	-12%	-14%	-36%	3.9%	-52%	-43%	11%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	7776 株式会社セルシード ISIN: JP3423530009 Shares Out.: Shares Outstanding: 39.16M¹ Shares Float: 38.551M² TV: TradingView: TSE: 7776 SA: Stock Analysis: TYO: 7776 YF: Yahoo Finance: 7776.T GF: Google Finance: TYO: 7776 BA: Barron's: 7776 MS: Morningstar: XTKS: 7776	269 JPY	TV: TradingView: TSE: 7776 SA: Stock Analysis: TYO: 7776 YF: Yahoo Finance: 7776.T GF: Google Finance: TYO: 7776 BA: Barron's: 7776 MS: Morningstar: XTKS: 7776

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CellSeed Inc.

CellSeed Inc. engages in the cell sheet regenerative medicine business in Japan, the rest of Asia, and Europe. It operates through Regenerative Medicine Support Business and Cell Sheet Regenerative Medicine Business segments. The company is involved in commercializing regenerative medicine using cell sheets, which include autologous and allogeneic chondrocyte sheets. It also offers regenerative medicine contract services comprising contract development and manufacturing; contract manufacturing and consulting for specified cell-based products; and training and education in cell culturing technology services. In addition, the company provides UpCell, a temperature-responsive cell cultureware for cell sheet engineering; RepCell, a temperature-responsive cell cultureware for cell collection; HydroCell, a low cell binding cultureware; ThermoPlate III, a heating element made of a transparent glass plate; cellZscope, an automated cell monitoring system; and cell sheet support products. CellSeed Inc. was incorporated in 2001 and is headquartered in Koto, Japan.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Japan)

Name	Market Cap (USD) diff.	PE	Country
Hisamitsu Pharmaceutical Co., Inc. TSE: 4530	$2.66B 425.23B JPY 4K%	22.5	Japan
Torii Pharmaceutical Co., Ltd. TSE: 4551	$1.11B 178.26B JPY 2K%	33.0	Japan
Euglena Co., Ltd. TSE: 2931	$350.57M 56.12B JPY 421%	-	Japan
Yomeishu Seizo Co.,Ltd. TSE: 2540	$347.7M 55.66B JPY 417%	74.9	Japan
AnGes, Inc. TSE: 4563	$128.51M 20.57B JPY 91%	-	Japan
Astena Holdings Co., Ltd. TSE: 8095	$121.54M 19.46B JPY 81%	8.6	Japan

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$36.75B 108.92B ILS 55K%	24.2	Israel
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 44K%	-	United States
Zhejiang NHU Company Ltd. SHE: 002001	$15.84B 107.34B CNY 23K%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.16B 1.06T INR 16K%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.04B 1.05T INR 16K%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.09B 61.6B CNY 13K%	80.6	China

chevron_leftBack